Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7306 to 7320 of 7707 results

  1. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    28 May 2003

  3. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    In development [GID-TA11007] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.

    Technology appraisal guidance
    Published
    12 June 2024

  5. GaitSmart assessment and vGym personalised exercise rehabilitation programme for people with gait and mobility issues (MIB283)

    This medtech innovation briefing (MIB) has been replaced by NICE medical technologies guidance on GaitSmart rehabilitation exercise programme for gait and mobility issues.

    Medtech innovation briefing
    Published
    1 February 2022

  6. AposHealth for knee osteoarthritis (MIB284)

    This medtech innovation briefing has been updated and replaced by NICE medical technologies guidance 76. 

    Medtech innovation briefing
    Published
    1 February 2022

  7. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    This guidance has been updated and replaced by NICE diagnostics guidance 60.

    Medtech innovation briefing
    Published
    7 March 2023

  8. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

    This guidance has been updated and replaced by NICE technology appraisal guidance 780.

    Technology appraisal guidance
    Published
    15 May 2019

  9. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development [GID-TA11146] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Technology appraisal guidance
    Published
    8 May 2019

  11. Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

    In development [GID-TA11631] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Venglustat for treating gangliosidoses in people 2 years and over ID 6358

    In development [GID-TA11601] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    In development [GID-TA11074] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    In development [GID-TA11009] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Surgical correction of hallux valgus using minimal access techniques (IPG332)

    This guidance has been updated and replaced by NICE interventional procedures guidance 789. 

    Interventional procedures guidance
    Published
    24 February 2010